

Hadar Goldvaser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6968495/publications.pdf>

Version: 2024-02-01

66
papers

818
citations

623734

14
h-index

552781

26
g-index

68
all docs

68
docs citations

68
times ranked

1310
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 31-39.	6.3	129
2	Tumor cells derived exosomes contain hTERT mRNA and transform nonmalignant fibroblasts into telomerase positive cells. <i>Oncotarget</i> , 2016, 7, 59173-59188.	1.8	93
3	Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. <i>Breast</i> , 2021, 60, 62-69.	2.2	88
4	Role of Bisphosphonates in Breast Cancer Therapy. <i>Current Treatment Options in Oncology</i> , 2019, 20, 26.	3.0	43
5	Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 531-545.	2.5	42
6	Characterisation of blood-derived exosomal hTERT mRNA secretion in cancer patients: a potential pan-cancer marker. <i>British Journal of Cancer</i> , 2017, 117, 353-357.	6.4	38
7	Colorectal cancer in young patients: is it a distinct clinical entity?. <i>International Journal of Clinical Oncology</i> , 2016, 21, 684-695.	2.2	35
8	Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1798-1804.	1.6	27
9	The association between smoking and breast cancer characteristics and outcome. <i>BMC Cancer</i> , 2017, 17, 624.	2.6	25
10	Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis. <i>Breast</i> , 2021, 58, 173-181.	2.2	23
11	Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 60, 53-59.	7.7	21
12	Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3369-3379.	2.5	21
13	Malignancy associated SIADH: Characterization and clinical implications. <i>Acta Oncologica</i> , 2016, 55, 1190-1195.	1.8	20
14	Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz033.	2.9	20
15	Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 413-425.	2.5	14
16	Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity. <i>World Journal of Gastroenterology</i> , 2017, 23, 1387.	3.3	14
17	Efficacy of immune checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2020, 9, 7613-7625.	2.8	12
18	Comparison of published and unpublished phase I clinical cancer trials: an analysis of the ClinicalTrials.gov database. <i>Investigational New Drugs</i> , 2018, 36, 933-938.	2.6	10

#	ARTICLE	IF	CITATIONS
19	Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. <i>Mayo Clinic Proceedings</i> , 2019, 94, 74-83.	3.0	10
20	Prognostic Value of the Detection of Lymphovascular Invasion in Hormone Receptor-Positive Early Breast Cancer in the Era of Molecular Profiling. <i>Oncology</i> , 2019, 96, 14-24.	1.9	10
21	Perception of prognosis of cancer patients by non-oncologists. <i>International Journal of Clinical Practice</i> , 2016, 70, 1027-1032.	1.7	9
22	Screening for occult cancer in idiopathic venous thromboembolism " Systemic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2017, 42, 74-80.	2.2	9
23	Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications. <i>Investigational New Drugs</i> , 2017, 35, 827-833.	2.6	9
24	Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 71, 68-75.	7.7	9
25	Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 138-143.	7.7	9
26	Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock. <i>JACC: CardioOncology</i> , 2019, 1, 141-144.	4.0	8
27	Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?. <i>Medicine (United States)</i> , 2021, 100, e26388.	1.0	8
28	Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 & 12 in Breast Cancer Patients: A Retrospective Analysis. <i>PLoS ONE</i> , 2014, 9, e107273.	2.5	7
29	Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2415-2418.	3.0	7
30	The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-9.	1.5	5
31	Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. <i>Cancer Medicine</i> , 2020, 9, 7888-7895.	2.8	5
32	High Lung Cancer Incidence in Heavy Smokers Following Hospitalization due to Pneumonia. <i>American Journal of Medicine</i> , 2016, 129, 332-338.	1.5	4
33	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. <i>Cancer Treatment Reviews</i> , 2020, 91, 102113.	7.7	4
34	The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. <i>Cancer Medicine</i> , 2020, 9, 4603-4612.	2.8	3
35	Fractionation scheme and treatment planning method for early glottic cancer in the United States: Economic impact of different medical decisions. <i>Head and Neck</i> , 2020, 42, 1713-1720.	2.0	3
36	Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 379-387.	2.5	3

#	ARTICLE	IF	CITATIONS
37	The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102293.	7.7	3
38	Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. <i>Annals of Hematology</i> , 2021, 100, 2879-2887.	1.8	3
39	Molecularly Confirmed Female Donor-Transmitted Lobular Breast Cancer to Male following Renal Transplantation. <i>Pathobiology</i> , 2023, 90, 63-68.	3.8	3
40	Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2017, 59, 46-53.	7.7	2
41	Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual. <i>JAMA Oncology</i> , 2019, 5, 107.	7.1	2
42	Incidence of lung cancer following pneumonia in smokers: a population-based study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, , .	0.5	2
43	The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer. <i>Discover Oncology</i> , 2021, 12, 26.	2.1	2
44	COVID-19 in a patient receiving adjuvant breast cancer chemotherapy with granulocyte colony-stimulating factor (G-CSF) support: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 14, 117.	1.0	1
45	Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade. <i>Scientific Reports</i> , 2021, 11, 10843.	3.3	1
46	Toxicity of extended adjuvant aromatase inhibitors therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 549-549.	1.6	1
47	The association between treatment for metabolic disorders and breast cancer characteristics.. <i>Journal of Clinical Oncology</i> , 2016, 34, 527-527.	1.6	1
48	Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 259-266.	2.5	0
49	The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1086-1086.	1.6	0
50	Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6571-6571.	1.6	0
51	The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer. <i>Oncology</i> , 2021, 99, 713-721.	1.9	0
52	Response to Soran et Al.. <i>Breast</i> , 2021, 60, 306-307.	2.2	0
53	Colorectal cancer in young patients: Is it a distinct clinical entity?. <i>Journal of Clinical Oncology</i> , 2015, 33, e14594-e14594.	1.6	0
54	The association between antihypertensive medications and breast cancer characteristics.. <i>Journal of Clinical Oncology</i> , 2016, 34, e12000-e12000.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Malignancy associated SIADH: Characterization and clinical implications.. Journal of Clinical Oncology, 2016, 34, e21622-e21622.	1.6	0
56	Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity.. Journal of Clinical Oncology, 2017, 35, 552-552.	1.6	0
57	De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2019, 37, 524-524.	1.6	0
58	The impact of exogenous estrogen exposure on the characteristics of estrogen receptor (ER) positive, early-stage breast cancer (EBC).. Journal of Clinical Oncology, 2020, 38, e12606-e12606.	1.6	0
59	Efficacy of immune check point inhibitors (ICIs) in metastatic gastric or gastroesophageal junction (GEJ) cancer by patient subgroups: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2020, 38, e16587-e16587.	1.6	0
60	Associations between safety and tolerability and reporting of health-related quality of life in phase III randomized trials in common solid tumors.. Journal of Clinical Oncology, 2020, 38, e19206-e19206.	1.6	0
61	The impact of endogenous estrogen exposure on the characteristics of estrogen receptor (ER) positive, early-stage breast cancer (EBC).. Journal of Clinical Oncology, 2020, 38, e12605-e12605.	1.6	0
62	NIMG-06. GUILLAIN BARRE MIMICKING LEPTOMENINGEAL SPREAD IN CANCER PATIENTS: REPORT OF TWO CASES AN REVIEW OF LITERATURE. Neuro-Oncology, 2020, 22, ii147-ii148.	1.2	0
63	Abstract P2-11-16: Rate of breast biopsy referrals in <i>BRCA</i> mutation carriers: A retrospective comparative study and matched analysis. Cancer Research, 2022, 82, P2-11-16-P2-11-16.	0.9	0
64	Germline Pathogenic Variants in <i>BRCA1</i> and <i>BRCA2</i>: Malignancies Beyond Female Breast and Ovarian Cancers. Journal of Clinical Oncology, 2022, , JCO2200003.	1.6	0
65	Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis. Breast Cancer Research and Treatment, 2022, , 1.	2.5	0
66	Recurrence Score (RS) results, clinicopathologic characteristics, treatments, and outcomes in primary versus subsequent breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.. Journal of Clinical Oncology, 2022, 40, 565-565.	1.6	0